PRANDIN

This brand name is authorized in United States. It is also authorized in Austria, Croatia, Estonia, Ireland, Italy, Lithuania, Poland, Spain, UK.

Active ingredients

The drug PRANDIN contains one active pharmaceutical ingredient (API):

1	Repaglinide UNII 668Z8C33LU - REPAGLINIDE
	Repaglinide is a short-acting oral secretagogue. Repaglinide lowers the blood glucose levels acutely by stimulating the release of insulin from the pancreas, an effect dependent upon functioning β-cells in the pancreatic islets.
	Read more about Repaglinide

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
PRANDIN Tablet	MPI, US: SPL/PLR	FDA, National Drug Code (US)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
A10BX02	Repaglinide	A Alimentary tract and metabolism → A10 Drugs used in diabetes → A10B Blood glucose lowering drugs, excl. insulins → A10BX Other blood glucose lowering drugs, excl. insulins
Discover more medicines within A10BX02

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
EE	Ravimiamet	1197457, 1197468, 1197479, 1197491, 1197503, 1197514, 1197536, 1197547, 1197558, 1304895, 1304907, 1304918
ES	Centro de información online de medicamentos de la AEMPS	00162004, 00162010, 00162016
IT	Agenzia del Farmaco	035252016, 035252028, 035252030, 035252042, 035252055, 035252067, 035252079, 035252081, 035252093, 035252105, 035252117, 035252129, 035252131, 035252143, 035252156, 035252168, 035252170, 035252182
LT	Valstybinė vaistų kontrolės tarnyba	1030374, 1030375, 1030376, 1030377, 1030378, 1030382, 1030383, 1030384, 1030385, 1030386, 1030387, 1030388, 1030389, 1030390, 1030391
PL	Rejestru Produktów Leczniczych	100313049, 100313204, 100313210
US	FDA, National Drug Code	0169-0081, 0169-0082, 0169-0084, 60846-882, 60846-884